about
Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and RepairRNase L contributes to experimentally induced type 1 diabetes onset in mice.Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes.Function and regulation of self-reactive marginal zone B cells in autoimmune arthritis.Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 Diabetes.Subcongenic analyses reveal complex interactions between distal chromosome 4 genes controlling diabetogenic B cells and CD4 T cells in nonobese diabetic mice.B-cell cross-presentation of autologous antigen precipitates diabetes.The pathogenesis and natural history of type 1 diabetes.Non-antigenic and antigenic interventions in type 1 diabetesB-lymphocyte depletion with rituximab and β-cell function: two-year resultsMechanisms of Regulatory B cell Function in Autoimmune and Inflammatory Diseases beyond IL-10.B cells as effectors and regulators of autoimmunity.Anti-inflammatory therapy in type 1 diabetes.Role of B lymphocytes in the pathogenesis of type 1 diabetes.Anti-serum with anti-autoantibody activity decreases autoantibody-positive B lymphocytes and type 1 diabetes of female NOD mice.Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis.B-lymphocyte therapy for Type 2 diabetes: the 'B' side of diabetic medication?Contribution of both B-cell intrinsic alterations as well as non-hematopoietic-derived factors in the enhanced immune response of the NOD mouse.Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
P2860
Q28078211-687B162F-3BA9-4926-A2C5-1E17A053824DQ34475565-A3804216-8179-4157-A229-D2043D95BA62Q35053311-8220ABAA-B820-4B01-A4E8-D4E3A3920E7DQ35833649-C0379432-B2BA-434B-AD92-A666DDF9FFFDQ35856862-A3AC0817-EDFB-4CF4-B8EC-B1C454255B32Q36106586-C817202B-95E4-42A8-9524-C262C21C0697Q36339548-3A585695-B851-4806-82FA-65F0B3FAD126Q36526611-872585A6-FA0D-4A5B-877C-5D4FF8BB1FCAQ36977725-C5F6B764-A014-4098-9F5D-543F699C03B6Q37504134-31640F35-5040-4B1E-B68E-CAB8E849293FQ37628188-44267A6B-3D15-47BC-81BA-364558A1C742Q37995319-DA298E91-56D3-42DC-98F1-A41113DD9218Q38025979-F6BC18F2-1F9E-4D89-AEDD-D8FAD5B8EEF4Q38246133-79ABECC0-DD0C-4A8D-90FD-BF2BA23C3AA2Q41428260-FECC73AE-A78B-48F9-983C-7D7815F19AEBQ41879482-C93F9D88-78CD-4BF0-8915-753ADD0B7865Q50856295-FC189894-3C36-40AC-BEFC-BFF29405E02EQ52763285-0AC84807-5BEE-4818-B30E-52B69C1DB217Q58773667-FE47F5E6-DB7B-4D48-98D2-46A6C17766B2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
B cell-directed therapies in type 1 diabetes.
@en
B cell-directed therapies in type 1 diabetes.
@nl
type
label
B cell-directed therapies in type 1 diabetes.
@en
B cell-directed therapies in type 1 diabetes.
@nl
prefLabel
B cell-directed therapies in type 1 diabetes.
@en
B cell-directed therapies in type 1 diabetes.
@nl
P2093
P356
P1433
P1476
B cell-directed therapies in type 1 diabetes.
@en
P2093
Eliana Mariño
Jessica Stolp
Shane T Grey
P304
P356
10.1016/J.IT.2011.03.006
P577
2011-04-29T00:00:00Z